<?xml version="1.0" encoding="UTF-8"?>
<p>Domain III of the ZIKV-envelope protein (EDIII) shares 29% amino-acid identity with DENV-EDIII and 90% of EDIII-antibodies (EDIII-Abs) elicited by ZIKV infection are virus specific [
 <xref rid="pntd.0007747.ref017" ref-type="bibr">17</xref>]. ZIKV EDIII-Abs tested in ELISA do not bind to DENV-2 or West-Nile virus (WNV) -EDIII [
 <xref rid="pntd.0007747.ref018" ref-type="bibr">18</xref>]. Studies in mice have shown that treatment with EDIII-Abs protect against ZIKV infection [
 <xref rid="pntd.0007747.ref019" ref-type="bibr">19</xref>] by neutralizing the virus [
 <xref rid="pntd.0007747.ref018" ref-type="bibr">18</xref>].
</p>
